# First-in-human Trial of STC-1010, an Immunotherapy, in Patients With Unresectable Locally Advanced or Metastatic Colorectal Cancer

Source: https://onco.cc/trials/nct06934538/  
OnCo record `nct06934538` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of STC-1010 + IS regimen + SOC therapy in colorectal cancer, run by Brenus Pharma, now recruiting.

## Summary

First-in-human Trial of STC-1010, an Immunotherapy, in Patients With Unresectable Locally Advanced or Metastatic Colorectal Cancer is a phase 1/2 interventional study registered as NCT06934538 by Brenus Pharma, with 90 participants planned, started 2025-06-17 and due to reach its primary completion in 2028-06. Interventions recorded: STC-1010 + IS regimen + SOC therapy.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT06934538
- Phase: 1/2
- Setting: Open Label, Multicenter, Dose-escalation and Cohort-expansion Phase I/IIA Trial of STC-1010, an Immunotherapy, in Patients With Unresectable Locally Advanced or Metastatic Colorectal Cancer (CRC) - BreAK CRC Trial (BreAK for Brenus Anti-cancer)
- Sponsor: Brenus Pharma
- Enrolled: 90

## Sources

- ClinicalTrials.gov NCT06934538: https://clinicaltrials.gov/study/NCT06934538

## Connected records

- cancers: [Colorectal cancer](https://onco.cc/cancers/colorectal/)

---
JSON: https://onco.cc/api/v1/entities/nct06934538.json